Trial Profile
LOw-Dose Tolvaptan in Decompensated Heart Failure Patients with Severe Aortic Stenosis - LOHAS registry -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2020
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Tolvaptan (Primary)
- Indications Decompensated heart failure; Heart failure
- Focus Therapeutic Use
- Acronyms LOHAS
- 13 Sep 2020 Status changed from active, no longer recruiting to completed.
- 01 Sep 2020 Primary endpoint ( Daily and 4-days total of Urine volume and Fluid balance) has not been met as per results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 01 Sep 2020 Primary endpoint (Change of body weight between admission and day 4) has been met as per results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology